Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. - Test2 - elhamkhani - TriplyDB

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

http://www.wikidata.org/entity/Q34157492

about

Intravenous immunoglobulin for Alzheimer's disease 11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)Lost in Translation (LiT): IUPHAR Review 6 Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores Revolutionizing Alzheimer's disease and clinical trials through biomarkers Induced pluripotent stem cells in Alzheimer's disease: applications for disease modeling and cell-replacement therapy Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged Current Research Therapeutic Strategies for Alzheimer's Disease Treatment Role of Hybrid Brain Imaging in Neuropsychiatric Disorders Suspected non-Alzheimer disease pathophysiology--concept and controversy Insights into Mechanisms of Chronic Neurodegeneration Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy β-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Gene expression parallels synaptic excitability and plasticity changes in Alzheimer's disease Anti-dementia medications: current prescriptions in clinical practice and new agents in progress Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015 Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics Genetic heterogeneity in Alzheimer disease and implications for treatment strategies Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression.Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials.Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab Targeting mRNA for Alzheimer's and related dementias.The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents Synaptopathies: synaptic dysfunction in neurological disorders - A review from students to students Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells Systems biology of neurodegenerative diseases Immunotherapeutic approaches for Alzheimer's disease

P2860

Q24188215-4402B90A-FC13-414D-816F-B5920F200DEF Q24194742-19504EA0-8F22-4447-BDE8-47DA8C76FDE3 Q24289150-ED0B8571-741A-49B9-947E-4AE3E6E6CA5E Q26382049-6790455E-D385-4E23-A2A5-26832CD8C58A Q26738355-DBF51972-7185-4E67-BEE3-A9B680633D1F Q26744882-1BA360E7-B6A1-4198-91B7-2ED48486D521 Q26749360-06D6100A-2559-4959-9BD0-9841B45B8A1F Q26752508-ADACF7A4-BF05-4709-A493-92DF2A2433A2 Q26765530-FC27B21C-E70E-4023-9F11-013FD7082478 Q26768454-A40AC5AA-75D9-414C-ABD0-6BE3C6AC53A6 Q26771270-B8C02249-6708-4E2F-9594-BBF9564C01AA Q26771732-762FAB0C-28E1-4A98-993B-C5100C8357AA Q26774743-0E983B4A-DFDE-44DF-B917-093A66B650F3 Q26781451-73C481D6-F4B9-4F27-BA96-0FD66087DB11 Q26781608-0F2446F0-EB86-4F62-80FE-F93ABB323923 Q26784569-4D9BD11C-8A93-44FD-9D38-62EC0AEB716D Q26785375-D6BDAE57-E55D-4D21-BE66-5EBCC9A5AC8F Q26795400-B5AC6B1E-6731-44BD-8897-829BE33269E2 Q26795492-9B97147C-658A-4EE1-87EA-9D83909D9ACA Q26801629-1D33A447-8927-485A-8997-AF4EA8440BE2 Q26801647-0BCF14E7-2E86-4EFE-BF03-7DEEF6B38D34 Q26801654-5DBE4C6D-B4D3-41DD-9E16-6FD47ED7D0CD Q26822002-BEB87D2B-F31A-4B39-83E8-E5DA74A82AF3 Q26995802-5AEB4DBC-120E-4823-B052-C9F58A8869DF Q27003841-3BB7A830-4BDC-4EAF-B041-2794C18682B6 Q27007436-BB5E7D69-B90E-47D8-A9F7-D785FA5D6593 Q27301267-71FE2061-192A-4B9D-AAA8-A0570C41CDE8 Q27303745-F25A0415-C3AA-4EEE-814F-66F3ED6E44B5 Q27310276-E5F03421-A8E1-4BE5-A140-B9CC3558FA19 Q27324311-A4C4AF03-3DBB-499F-A68E-22DD75A5B49B Q27684692-BBA296F5-B841-4D5E-B981-7B87FA0526BD Q27687153-6296C49D-EF46-440E-A082-299541EC9E2A Q28005463-16379FB4-B73F-4928-9EF3-294548BFA7E7 Q28066906-F8E97C52-E668-44F1-98D8-0705762398AF Q28072061-8F1E44B4-C026-497A-9A96-9567BFB76385 Q28075692-FB4628FF-41F9-4992-91C0-1642F0978602 Q28077671-E01AB583-CAB2-467A-9A48-F8ABCAEE2B23 Q28079063-9069B2DE-49BD-456E-8CB8-37F201F30252 Q28080741-AFCC5147-59DA-4EBF-AB39-2D29C9CBBD35 Q28081278-20FD2266-69F3-44A3-90A2-1473D098675A

P2860

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

http://www.wikidata.org/entity/Q34157492

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@ast

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@en

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@nl

type

label

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@ast

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@en

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@nl

prefLabel

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@ast

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@en

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@nl

P1433

Q34157492-FBD9A0D4-56A3-4ACC-8EE0-0EC86D7B46B5

P1476

Q34157492-126971DF-B5D5-4F3A-893A-3A0BA400600F

P2093

Q34157492-047C31AA-5D22-4A45-B098-98799E599A0B

Q34157492-4B7CF8AA-3752-40C4-A02B-C7BF27B5B856

Q34157492-4CA4434C-5531-4027-BC44-96BB7EE6421D

Q34157492-4DC074AB-BC93-4E9F-9B2C-F91937A231DC

Q34157492-6BA478ED-CF68-4E17-BDB9-02A9066FA950

Q34157492-7F5C574A-83D4-4875-B290-BFA4F498267D

Q34157492-82BCFE86-DC75-4CE4-BD74-69D93F01FECD

Q34157492-8371B68C-DDD8-4649-B6BE-E25CA0784145

Q34157492-9FEBA1B4-0225-4679-8DB1-6543E72FA6B5

Q34157492-A195F9ED-9676-43F1-A79F-2A01D174A675

P2860

Q34157492-001F3462-BA17-42BB-9DF7-3CB5D4FF1498

Q34157492-0FF95434-EB43-4DD8-AFEF-8A72FEAC1780

Q34157492-11639C72-338A-4E26-9348-AD8D9597839D

Q34157492-15721B54-4B7D-46F8-B7D9-5216C7FB8F77

Q34157492-15DF0378-D505-4D91-A202-210CC380F54A

Q34157492-4D9FF9F9-6B3E-4F8D-AA15-1D99BAAF132E

Q34157492-4DC59FD7-013C-4C78-8A76-128E18D93D2E

Q34157492-57594B94-7A50-4791-BE79-8596B32EF13B

Q34157492-597F6FF2-F97B-4C55-810E-FFF55B4834F3

Q34157492-5EA446E7-4A7D-4531-B322-E2ED8C20B542

P304

Q34157492-AFE6AD91-82F8-4B1C-8C11-EC48F9387940

P31

Q34157492-8A76263E-A88A-41DD-8BB6-6BFE2E9A0C4F

P356

Q34157492-A3A6C323-4447-449C-A537-647C66B42C1C

P407

Q34157492-09DFFF1D-A545-4D64-A561-4A93464FC0B4

P433

Q34157492-630CF99E-24F9-40A6-9982-175F08E527DD

P478

Q34157492-22A9C96B-533B-4565-B4E3-5AA6BB81E52C

P50

Q34157492-505C7D36-B4D0-4F88-9299-A7D7BB3808E8

Q34157492-8A0F166A-F827-4C0F-8D83-0A03DE01293B

Q34157492-B4987BC7-0500-485F-AB98-29327327BBA8

Q34157492-B81BCF8D-823F-4DD6-80E6-0EDA6C3D215F

Q34157492-E308125B-FCC2-4C7F-B672-49601C74F530

P577

Q34157492-D674C034-2060-4993-9DD0-7DEAF3019350

P698

Q34157492-50C875C1-D719-473F-80CC-F52F3CA61C06

P921

Q34157492-2BB09108-2998-49FF-AA26-6546AC629872

Q34157492-FADACA6C-0ECB-4488-8107-D039AC169490

P932

Q34157492-9E3AA6DE-956D-47EF-9034-2A6CFBFA31D3

P356

P1433

The New England Journal of Medicine

P1476

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

@en

P2093

Anton P Porsteinsson

http://www.w3.org/2001/XMLSchema#string

Bapineuzumab 301 and 302 Clinical Trial Investigators

http://www.w3.org/2001/XMLSchema#string

Bijan Nejadnik

http://www.w3.org/2001/XMLSchema#string

Daniel Wang

http://www.w3.org/2001/XMLSchema#string

Enchi Liu

http://www.w3.org/2001/XMLSchema#string

Eric Yuen

http://www.w3.org/2001/XMLSchema#string

H Robert Brashear

http://www.w3.org/2001/XMLSchema#string

Iulia Cristina Tudor

http://www.w3.org/2001/XMLSchema#string

Julia Lull

http://www.w3.org/2001/XMLSchema#string

Lawrence S Honig

http://www.w3.org/2001/XMLSchema#string

P2860

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

“Mini-mental state”

Testing the right target and right drug at the right stage

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

The Clinical Dementia Rating (CDR): current version and scoring rules

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.

P304

322-333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1304839

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

William E. Klunk

Steven H Ferris

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24450891

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

phase III clinical trial

P932

4159618

http://www.w3.org/2001/XMLSchema#string